| Pharmaceuticals - Diabetes Care | Long-acting insulins, premix insulin formulations, insulin delivery devices | Strong market share, brand recognition, innovative insulin pens, and digital capabilities | Hospitals, clinics, diabetic patients (B2B and B2C) | Insulin analogs and innovative delivery devices | 1000 | 50 | Product sales through distributors and healthcare providers | Direct sales with competitive pricing and product offerings | Increasing diabetes prevalence, new product launches, digital outreach, public sector expansion | Lantus, Toujeo, Soliqua, Toustar pen |
| Pharmaceuticals - General Medicines (Cardiovascular, CNS, Anti-infectives) | Anti-inflammatory, anti-diabetic, allergy, cardiovascular treatments | Recognized brands with wide distribution and physician trust | Doctors, hospitals, retail pharmacies, patients | Established cardiovascular and CNS medicines | 800 | 40 | Sales through pharmacies and medical practitioners | Direct product sales with established brand loyalty | Legacy brand strength, product line extensions, chronic disease management | Combiflam, Amaryl, Allegra, Cardace H |
| Export and Others | Pharmaceutical exports and miscellaneous income | Part of global supply chain network | International partners and distributors | Niche export products | 200 | 10 | Export sales and service income | Contract-based sales | Expanding export markets, diverse product mix | |
